BRPI1008727B8 - derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson - Google Patents

derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson

Info

Publication number
BRPI1008727B8
BRPI1008727B8 BRPI1008727A BRPI1008727A BRPI1008727B8 BR PI1008727 B8 BRPI1008727 B8 BR PI1008727B8 BR PI1008727 A BRPI1008727 A BR PI1008727A BR PI1008727 A BRPI1008727 A BR PI1008727A BR PI1008727 B8 BRPI1008727 B8 BR PI1008727B8
Authority
BR
Brazil
Prior art keywords
disease
derivatives
pharmaceutical composition
parkinson
composition containing
Prior art date
Application number
BRPI1008727A
Other languages
English (en)
Inventor
Park Cheol-Hyoung
Ryu Choon-Ho
Min Hye-Kyung
Chung Jin-Yong
Lee Ji-Won
Park Joo-Young
Mi-Jung-Lim
Ji Mi-Kyung
Yoon Yeo-Jin
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of BRPI1008727A2 publication Critical patent/BRPI1008727A2/pt
Publication of BRPI1008727B1 publication Critical patent/BRPI1008727B1/pt
Publication of BRPI1008727B8 publication Critical patent/BRPI1008727B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos. a presente invenção refere-se a um derivado de azol substituído e sais farmaceuticamente aceitáveis dos mesmos, uma composição farmacêutica incluindo uma quantidade eficaz do derivado, e um método para o tratamento da doença de parkinson em um mamífero incluindo a administração de uma quantidade eficaz do composto ao mamífero. o derivado de azol da seguinte fórmula (i) e sais farmaceuticamente aceitáveis dos mesmos possuem uma eficácia contra a doença de parkinson a partir dos efeitos inibidores da atividade de mao-b.
BRPI1008727A 2009-02-25 2010-02-25 derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson BRPI1008727B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20090015856 2009-02-25
KR10-2009-0015856 2009-02-25
KR10-2010-0016686 2010-02-24
KR1020100016686A KR101220182B1 (ko) 2009-02-25 2010-02-24 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
PCT/KR2010/001186 WO2010098600A2 (en) 2009-02-25 2010-02-25 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same

Publications (3)

Publication Number Publication Date
BRPI1008727A2 BRPI1008727A2 (pt) 2016-03-08
BRPI1008727B1 BRPI1008727B1 (pt) 2020-07-28
BRPI1008727B8 true BRPI1008727B8 (pt) 2021-05-25

Family

ID=43004459

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008727A BRPI1008727B8 (pt) 2009-02-25 2010-02-25 derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson

Country Status (13)

Country Link
US (1) US8828992B2 (pt)
EP (1) EP2401263B1 (pt)
JP (1) JP5717031B2 (pt)
KR (1) KR101220182B1 (pt)
CN (1) CN102333764B (pt)
AU (1) AU2010218584B2 (pt)
BR (1) BRPI1008727B8 (pt)
CA (1) CA2751343C (pt)
ES (1) ES2566482T3 (pt)
MX (1) MX2011008910A (pt)
PL (1) PL2401263T3 (pt)
RU (1) RU2578596C2 (pt)
WO (1) WO2010098600A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2817304A4 (en) * 2011-07-14 2015-01-21 Biochromix Newco Ab Novel compounds and their use in therapy
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
NZ711598A (en) 2013-03-14 2016-09-30 Dart Neuroscience Cayman Ltd Substituted naphthyridine and quinoline compounds as mao inhibitors
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
CN107207488B (zh) * 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
KR101896398B1 (ko) * 2017-11-14 2018-09-07 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
CN108676001A (zh) * 2018-06-12 2018-10-19 江西师范大学 一种3-取代-5-异噁唑基-4-取代-1-1,2,3-三氮唑基甲烷化合物
US11517548B2 (en) * 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
KR20200109537A (ko) 2019-03-13 2020-09-23 충북대학교 산학협력단 1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(4-((5-(트리플루오로메틸)피리딘-2-일)옥시)사이클로헥실)유레아를 유효성분으로 하는 파킨슨 질환 예방 또는 치료용 약학적 조성물
KR102186761B1 (ko) 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
CN117327000A (zh) * 2023-10-07 2024-01-02 海南因瑞生物医药科技有限公司 一种联苯四氢吡咯化合物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE248589C (pt)
NL256329A (pt) * 1959-09-29
GB965925A (en) * 1961-03-04 1964-08-06 Francesco Angelini Improvements in or relating to 1,2,4-oxadiazole derivatives
GB969813A (en) * 1962-03-26 1964-09-16 Francesco Angelini Improvements in or relating to 1,2,4-oxadiazole derivatives
US3245989A (en) 1962-12-15 1966-04-12 Acraf 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
NL302496A (pt) 1962-12-22
FR1386543A (fr) 1962-12-22 1965-01-22 Shionigi & Co Préparation de composés d'isoxazole et nouveaux produits ainsi obtenus
DD248589A1 (de) * 1986-04-24 1987-08-12 Univ Berlin Humboldt Verfahren zur herstellung von substituierten 1,2,4-triazolen
DD263987A1 (de) 1987-08-07 1989-01-18 Univ Berlin Humboldt Verfahren zur herstellung von 5-(omega-aminoalkyl)-1,2,4-oxadiazolsalzen
JPH04295470A (ja) 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
HUP9602763A3 (en) 1996-10-09 1999-05-28 Egyt Gyogyszervegyeszeti Gyar 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CN1151150C (zh) 2001-02-13 2004-05-26 王建武 一类非肽血管紧张素Ⅱ受体拮抗剂Jwsartan化合物及其合成方法与用途
AU2003221322A1 (en) 2002-03-07 2003-09-16 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
ES2329354T3 (es) 2002-04-26 2009-11-25 F. Hoffmann-La Roche Ag Derivados de isoquinolina.
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US7903538B2 (en) * 2003-08-06 2011-03-08 Intel Corporation Technique to select transmission parameters
BRPI0415842A (pt) * 2003-10-23 2007-01-02 Hoffmann La Roche derivativos de benzapepina como inibidores de mao-b
NZ595000A (en) 2003-12-22 2013-03-28 Gilead Sciences Inc Imidazo[4,5-c]pyridine derivative for treating viral infections
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
WO2006013049A2 (en) * 2004-08-02 2006-02-09 F.Hoffmann-La Roche Ag Benzyloxy derivatives as maob inhibitors
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN100488979C (zh) 2005-10-14 2009-05-20 天津药物研究院 甘草次酸-30-酰胺类衍生物及其用途
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
SG177221A1 (en) * 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
EA201000051A1 (ru) 2007-07-13 2010-08-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Противовирусные соединения, композиции и способы использования

Also Published As

Publication number Publication date
EP2401263A4 (en) 2012-11-28
ES2566482T3 (es) 2016-04-13
KR101220182B1 (ko) 2013-01-11
CN102333764A (zh) 2012-01-25
US8828992B2 (en) 2014-09-09
EP2401263A2 (en) 2012-01-04
BRPI1008727A2 (pt) 2016-03-08
MX2011008910A (es) 2011-09-08
RU2011134423A (ru) 2013-04-10
CN102333764B (zh) 2016-01-06
CA2751343C (en) 2017-04-25
CA2751343A1 (en) 2010-09-02
HK1165798A1 (zh) 2012-10-12
EP2401263B1 (en) 2016-02-17
PL2401263T3 (pl) 2016-08-31
JP2012518683A (ja) 2012-08-16
WO2010098600A3 (en) 2011-01-06
AU2010218584B2 (en) 2015-12-03
WO2010098600A2 (en) 2010-09-02
BRPI1008727B1 (pt) 2020-07-28
KR20100097059A (ko) 2010-09-02
AU2010218584A1 (en) 2011-08-18
RU2578596C2 (ru) 2016-03-27
US20110301150A1 (en) 2011-12-08
JP5717031B2 (ja) 2015-05-13

Similar Documents

Publication Publication Date Title
BRPI1008727B8 (pt) derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
BR112012006010A2 (pt) composto de glicina
PH12015501678A1 (en) Inhibitors of influenza viruses replication
BRPI0914404A2 (pt) "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
BRPI0911444B8 (pt) benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
BRPI0708071A8 (pt) Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
ATE427941T1 (de) Thiazolderivate mit vap-1-hemmender wirkung
BR112022006572A2 (pt) Inibidores orais do fator d do complemento
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
CR10410A (es) Carboxamidas sustituidas.
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.